Jyhhaw Liu's questions to Phathom Pharmaceuticals (PHAT) leadership • Q2 2025
Question
Jyhhaw Liu, on behalf of Umer Raffat at Evercore ISI, asked about Phathom's ex-U.S. strategy and whether patients cycling through multiple PPIs before trying Voquezna is due to step-edits or physician prescribing patterns.
Answer
Steven Basta, President, CEO & Director, stated that the company is currently focused exclusively on the U.S. market. He explained that patients failing multiple PPIs reflects the high unmet need among GERD patients, and the company's long-term goal is to shift physician behavior to prescribe Voquezna immediately after a single PPI failure.